Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072061 | 1.00 | NR1H2 (0.38) | NR1H2NR1H3FFAR1KCNH2GPR119 | |
| SCHEMBL20072186 | 1.00 | NR1H2 (0.38) | NR1H2NR1H3FFAR1KCNH2GPR119 | |
| SCHEMBL21644266 | 0.90 | NR1H2 (0.45) | NR1H2NR1H3KCNH2GPR119 | |
| SCHEMBL21686417 | 0.90 | NR1H2 (0.45) | NR1H2NR1H3KCNH2GPR119 | |
| SCHEMBL21644406 | 0.90 | NR1H2 (0.45) | NR1H2NR1H3KCNH2GPR119 | |
| SCHEMBL23824835 | 0.90 | NR1H2 (0.45) | NR1H2NR1H3KCNH2GPR119 | |
| SCHEMBL21686416 | 0.90 | NR1H2 (0.45) | NR1H2NR1H3KCNH2GPR119 | |
| SCHEMBL20072185 | 0.90 | NR1H2 (0.45) | NR1H2NR1H3KCNH2GPR119 | |
| SCHEMBL20072138 | 0.90 | NR1H2 (0.41) | NR1H2NR1H3KCNH2GPR119CCR1 | |
| SCHEMBL21686407 | 0.90 | NR1H2 (0.41) | NR1H2NR1H3KCNH2GPR119CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526203-B1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2018068297-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885FFAR1 22/4885 |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885FFAR1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.